IL113436A0 - Neurotransmitter release enhancers - Google Patents
Neurotransmitter release enhancersInfo
- Publication number
- IL113436A0 IL113436A0 IL11343695A IL11343695A IL113436A0 IL 113436 A0 IL113436 A0 IL 113436A0 IL 11343695 A IL11343695 A IL 11343695A IL 11343695 A IL11343695 A IL 11343695A IL 113436 A0 IL113436 A0 IL 113436A0
- Authority
- IL
- Israel
- Prior art keywords
- pct
- sec
- disease
- compounds
- date
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/20—Quaternary compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23674394A | 1994-04-29 | 1994-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL113436A0 true IL113436A0 (en) | 1995-07-31 |
Family
ID=22890767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11343695A IL113436A0 (en) | 1994-04-29 | 1995-04-20 | Neurotransmitter release enhancers |
Country Status (14)
Country | Link |
---|---|
US (1) | US5854232A (de) |
EP (1) | EP0757685B1 (de) |
JP (4) | JP3004728B2 (de) |
AT (1) | ATE271553T1 (de) |
AU (1) | AU1884595A (de) |
CA (1) | CA2188427C (de) |
DE (1) | DE69533284T2 (de) |
DK (1) | DK0757685T3 (de) |
ES (1) | ES2223049T3 (de) |
FI (1) | FI964340A0 (de) |
IL (1) | IL113436A0 (de) |
MX (1) | MX9605218A (de) |
PT (1) | PT757685E (de) |
WO (1) | WO1995029909A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09183725A (ja) * | 1995-09-01 | 1997-07-15 | Pfizer Inc | ガン治療用治療剤 |
BR9709974A (pt) * | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
DK0870757T3 (da) * | 1997-04-10 | 2002-07-15 | Pfizer | Fluorsubstituerede adamantanderivater |
GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
EP1035160B1 (de) | 1997-11-25 | 2002-10-16 | Bratkova, Ljubov | Licht konvertierendes material und zusammensetzung zu dessen herstellung |
US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
EP1399155B1 (de) * | 1999-07-21 | 2008-05-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Kleine moleküle zur behandlung von endzündlichen erkrankungen |
US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
DE60143098D1 (de) * | 2000-05-31 | 2010-10-28 | Santen Pharmaceutical Co Ltd | (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren |
US7585523B2 (en) * | 2002-08-27 | 2009-09-08 | Targeted Medical Pharma | Composition and method to augment and sustain neurotransmitter production |
CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
ATE420881T1 (de) | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors |
CA2617760C (en) * | 2005-08-04 | 2015-02-17 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
US8168667B2 (en) | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
US7807846B2 (en) | 2006-09-27 | 2010-10-05 | Nissan Chemical Industries, Ltd. | Method for producing succinimide compound |
TW201010975A (en) | 2008-08-29 | 2010-03-16 | Kowa Co | 1-adamantylazetidin-2-one derivatives and drugs containing same |
GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN108610292B (zh) * | 2018-06-12 | 2020-11-10 | 清华大学 | 一类3,5-二取代乙内酰脲类化合物及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4216318A (en) * | 1975-12-29 | 1980-08-05 | Smith Kline & French Laboratories Limited | Heterocyclic alkyl 4-pyrimidones |
US5173489A (en) * | 1986-04-10 | 1992-12-22 | The Dupont Merck Pharmaceutical Co. | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers |
US4760083A (en) * | 1986-04-10 | 1988-07-26 | E. I. Dupont De Nemours & Company | 3,3-disubstituted indolines |
ATE250587T1 (de) * | 1989-06-14 | 2003-10-15 | Smithkline Beecham Corp | Imidazoalkensäure |
US5006537A (en) * | 1989-08-02 | 1991-04-09 | Hoechst-Roussel Pharmaceuticals, Inc. | 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones |
AU3425493A (en) * | 1992-01-16 | 1993-08-03 | Du Pont Merck Pharmaceutical Company, The | Novel neurotransmitter releasers useful for cognition enhancement |
US5278162A (en) * | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
DE69323768T2 (de) * | 1992-12-17 | 1999-07-01 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体 |
TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
-
1995
- 1995-03-20 AU AU18845/95A patent/AU1884595A/en not_active Abandoned
- 1995-03-20 JP JP7528089A patent/JP3004728B2/ja not_active Expired - Fee Related
- 1995-03-20 DE DE69533284T patent/DE69533284T2/de not_active Expired - Fee Related
- 1995-03-20 MX MX9605218A patent/MX9605218A/es not_active IP Right Cessation
- 1995-03-20 EP EP95910708A patent/EP0757685B1/de not_active Expired - Lifetime
- 1995-03-20 WO PCT/IB1995/000189 patent/WO1995029909A1/en active IP Right Grant
- 1995-03-20 CA CA002188427A patent/CA2188427C/en not_active Expired - Fee Related
- 1995-03-20 AT AT95910708T patent/ATE271553T1/de not_active IP Right Cessation
- 1995-03-20 US US08/737,376 patent/US5854232A/en not_active Expired - Fee Related
- 1995-03-20 ES ES95910708T patent/ES2223049T3/es not_active Expired - Lifetime
- 1995-03-20 DK DK95910708T patent/DK0757685T3/da active
- 1995-03-20 PT PT95910708T patent/PT757685E/pt unknown
- 1995-04-20 IL IL11343695A patent/IL113436A0/xx unknown
-
1996
- 1996-10-28 FI FI964340A patent/FI964340A0/fi not_active IP Right Cessation
-
1998
- 1998-10-13 JP JP29066498A patent/JP3432753B2/ja not_active Expired - Fee Related
- 1998-10-13 JP JP29063698A patent/JP3281320B2/ja not_active Expired - Fee Related
- 1998-10-13 JP JP29068298A patent/JP3158103B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69533284D1 (de) | 2004-08-26 |
EP0757685B1 (de) | 2004-07-21 |
MX9605218A (es) | 1997-10-31 |
FI964340A (fi) | 1996-10-28 |
WO1995029909A1 (en) | 1995-11-09 |
US5854232A (en) | 1998-12-29 |
JPH11217371A (ja) | 1999-08-10 |
JPH11209374A (ja) | 1999-08-03 |
FI964340A0 (fi) | 1996-10-28 |
DE69533284T2 (de) | 2005-07-21 |
DK0757685T3 (da) | 2004-10-25 |
JP3004728B2 (ja) | 2000-01-31 |
JPH09506371A (ja) | 1997-06-24 |
PT757685E (pt) | 2004-10-29 |
EP0757685A1 (de) | 1997-02-12 |
JP3281320B2 (ja) | 2002-05-13 |
CA2188427C (en) | 2000-06-27 |
ES2223049T3 (es) | 2005-02-16 |
JP3432753B2 (ja) | 2003-08-04 |
JPH11193273A (ja) | 1999-07-21 |
ATE271553T1 (de) | 2004-08-15 |
JP3158103B2 (ja) | 2001-04-23 |
AU1884595A (en) | 1995-11-29 |
CA2188427A1 (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL113436A0 (en) | Neurotransmitter release enhancers | |
GR3022459T3 (en) | Quinuclidine derivative as substance p antagonist. | |
GB9426103D0 (en) | Therapeutic agents | |
CA2366268A1 (en) | Pharmaceutical compositions for cns and other disorders | |
LU91751I2 (fr) | Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®) | |
MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
IL116083A0 (en) | Liquid pharmaceutical compositions containing ondansetron and their use | |
PL1678172T3 (pl) | Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego | |
IL114600A (en) | Thiazole and thiadiazole compounds their preparation and pharmaceutical compositions containing them | |
MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
IL114598A (en) | Triazole compounds their preparation and pharmaceutical compositions containing them | |
HU9602707D0 (en) | Tropane-2-aldoxine derivatives as neurotransmitter reuptake inhibitors | |
IL110349A0 (en) | Tetrahydro-1h- benzazepinones containing acid surrogates | |
NZ331769A (en) | Indolomorphinan derivative and agent for curing and preventing cerebral disorder | |
MXPA03002595A (es) | Aminoalquilpirrolidinas ligandos del receptor de serotonina y composiciones, sus usos farmaceuticos, y metodos para su sintesis. | |
EP0911334A4 (de) | Chinolinmorphinan-derivate und ihre medizinische anwendung | |
AU2796695A (en) | Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders | |
HK1098668A1 (en) | Use of 1,3-diaza-dibenzo Äe.hÜ azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | |
ES2141671A1 (es) | Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
MX9804631A (es) | Antagonistas quinazolin-4-ona del ampa. |